NCT04462822View on ClinicalTrials.gov

A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 24, 2020

Primary Completion Date

September 9, 2020

Study Completion Date

December 31, 2020

Conditions
Bioequivalence
Interventions
DRUG

Fluticasone propionate 250 mcg and salmeterol xinafoate 50 mcg/Respirent

2 inhalations of Test and Reference product in each study period

DRUG

ADVAIR DISKUS® 250/50

2 inhalations of Test and Reference product in each study period

Trial Locations (1)

41100

BECRO Clinical Facility, Larissa

All Listed Sponsors
collaborator

Becro Ltd.

INDUSTRY

lead

Respirent Pharmaceuticals Co Ltd.

INDUSTRY

NCT04462822 - A Pilot Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers | Biotech Hunter | Biotech Hunter